Ocular Immunology and Inflammation最新文献

{"title":"Aggressive Retinal vasculitis and Progressive Outer Retinal Atrophy Associated with Sjögren's Syndrome: A Case Report.","authors":"Xinzhu Hou, Ting Fang, Pingping Yu, Shengjia Hu","doi":"10.1080/09273948.2026.2735406","DOIUrl":"https://doi.org/10.1080/09273948.2026.2735406","url":null,"abstract":"<p><strong>Purpose: </strong>Aggressive retinal vasculitis (RV) and progressive outer retinal atrophy associated with Sjögren's syndrome (SS) are exceptionally rare. This case emphasizes the necessity for early recognition and monitoring of unexplained visual symptoms in patients with systemic autoimmune diseases.</p><p><strong>Methods: </strong>This case reported a 36-year-old female presenting with a six-month history of progressive bilateral vision loss preceded by persistent photopsia. The patient was diagnosed with non-infectious RV and outer retinal atrophy associated with SS according to ophthalmic multimodal screening and thorough systemic examinations. Genomic screening, serum tissue-based assay (TBA), serum tumor markers and classical paraneoplastic antibodies testing were performed to rule out hereditary retinopathy, autoimmune encephalitis, cancer-associated retinopathy (CAR) and other paraneoplastic visual syndromes.</p><p><strong>Results: </strong>A systemic anti-inflammatory and immunosuppressive therapy was initiated. However, it failed to arrest the relentless retinal atrophy. The patient experienced progressive visual field constriction, ultimately culminating in the irreversible disappearance of outer retinal structure despite systemic stabilization.</p><p><strong>Conclusion: </strong>Early cognition and standardized therapy of fundus lesions in SS patients need further study to avoid permanent visual loss. A more profound understanding of the relationship between SS and RV is needed to guide treatment.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-6"},"PeriodicalIF":1.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149075535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Acute Iris Transillumination and Bilateral Acute Depigmentation of the Iris: A Systematic Review and Meta-Analysis.","authors":"Furkan Ozer, Duygu Gülmez Sevim, Hidayet Sener","doi":"10.1080/09273948.2026.2735410","DOIUrl":"https://doi.org/10.1080/09273948.2026.2735410","url":null,"abstract":"<p><strong>Purpose: </strong>To systematically review and quantitatively synthesize the available evidence on bilateral acute iris transillumination (BAIT) and bilateral acute depigmentation of the iris (BADI), with particular emphasis on demographic characteristics, clinical findings, glaucoma-related outcomes, and potential disease modifiers.</p><p><strong>Methods: </strong>PubMed, Web of Science, and the Cochrane Library were systematically searched from database inception to May 1, 2026. Case reports, case series, and cohort studies reporting clinically diagnosed BAIT or BADI were included. Random-effects meta-analyses were performed for studies including at least four patients. Patient-level data from smaller case reports and case series (<4 patients) were aggregated separately to provide complementary descriptive estimates. Between-study heterogeneity, prediction intervals, and small-study effects were evaluated, and study-level random-effects meta-regression analyses were performed for BAIT.</p><p><strong>Results: </strong>Thirty-six BAIT studies and 18 BADI studies met the inclusion criteria. The primary meta-analysis included 153 BAIT patients (302 eyes) and 70 BADI patients (137 eyes). BAIT showed numerically higher pooled baseline intraocular pressure (21.93 vs. 14.94 mmHg), ocular hypertension frequency (48.9% vs. 9.2%), antiglaucoma medication use (48.6% vs. 12.2%), and glaucoma surgery rate (21.8% vs. 0.8%) than BADI. Meta-regression identified baseline intraocular pressure as a significant predictor of both glaucoma surgery and antiglaucoma medication requirements, while higher female proportion was associated with lower baseline intraocular pressure.</p><p><strong>Conclusions: </strong>Separate pooled analyses suggest a greater glaucoma-related burden in BAIT, characterized by more pronounced intraocular pressure elevation and greater treatment requirements. However, the observed differences between these clinical entities should be interpreted as descriptive patterns rather than direct between-group effect estimates.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-18"},"PeriodicalIF":1.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Comment on Azeem S, et al's \"Acute Retinal Necrosis-Associated Rhegmatogenous Retinal Detachment: A Systematic Review and Meta-Analysis\".","authors":"Srinivasan Sanjay, Moustafa S Magliyah","doi":"10.1080/09273948.2026.2737298","DOIUrl":"https://doi.org/10.1080/09273948.2026.2737298","url":null,"abstract":"","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-2"},"PeriodicalIF":1.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149075271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual Tattoo-Associated Uveitis After Cosmetic Eyebrow Tattooing: A Case Study and Narrative Review.","authors":"Wendy Yen Nee See, Derrick Jun Quan Chuah, Reena Kaur Balbit Singh, Norazita Ahmad Tarmizi","doi":"10.1080/09273948.2026.2740694","DOIUrl":"https://doi.org/10.1080/09273948.2026.2740694","url":null,"abstract":"<p><strong>Purpose: </strong>To report a case of unusual tattoo-associated uveitis following cosmetic eyebrow tattooing.</p><p><strong>Method: </strong>Case report with review of relevant literature.</p><p><strong>Result: </strong>A 37-year-old Chinese female presented with worsening blurring of vision and painful red right eye following repeated cosmetic eyebrow tattooing, which had caused local swelling and bleeding at the eyebrow tattoo site. Right visual acuity was 6/60. Ophthalmic examination showed right eye panuveitis with cystoid macular edema. A diagnosis of tattoo-associated uveitis was made after exclusion of other identifiable causes, including systemic sarcoidosis. Due to the severe, chronic and relapsing ocular inflammation, treatment was escalated from topical steroid, periocular corticosteroid, and low-dose systemic corticosteroid to higher-dose systemic corticosteroid, and ultimately immunosuppressive therapy to achieve clinical remission. She subsequently developed posterior subcapsular cataract, with final visual acuity improved to 6/18.</p><p><strong>Conclusion: </strong>Tattoo-associated uveitis following cosmetic eyebrow tattooing is an uncommon but likely underdiagnosed clinical entity. Ophthalmologists should maintain a high index of clinical suspicion and take a thorough history, including cosmetic tattooing in patients presenting with uveitis of unclear etiology, particularly given the growing global popularity of cosmetic tattooing.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-4"},"PeriodicalIF":1.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Spectrum of Subretinal Abscess: Insights from a 15-Year Single‑Center Experience.","authors":"Ankita Mitra, Sanchita Mitra, Raja Narayanan, Mudit Tyagi, Soumyava Basu","doi":"10.1080/09273948.2026.2740679","DOIUrl":"https://doi.org/10.1080/09273948.2026.2740679","url":null,"abstract":"<p><strong>Purpose: </strong>To report the clinical outcomes and microbiological spectrum of subretinal abscess (SRA) over a 15-year period at a tertiary eye care center in South India.</p><p><strong>Methods: </strong>Retrospective review of electronic medical records at a tertiary eye care institute for patients clinically diagnosed with SRA from 2009 to 2024. SRA was classified as tubercular (TB-SRA) and non-tubercular (non-TB SRA) based on clinical and microbiological evidence.</p><p><strong>Results: </strong>Forty-three patients (50 eyes) were included (83.7% male; 16.3% bilateral); 15 patients (34.9%) had TB-SRA and 28 (65.1%) had non-TB SRA. There was no significant difference in presenting visual acuity between TB-SRA vs non-TB SRA (1.82 ± 1.16 vs 2.15 ± 1.20 LogMAR; <i>p</i> = 0.18). Microbiological confirmation was less frequent in TB-SRA vs non-TB SRA (26.7% vs 60.7%; <i>p</i> = 0.03); common pathogens in non-TB SRA included <i>Staphylococcus</i>, <i>Klebsiella</i>, and <i>Aspergillus</i> while <i>Mycobacterium tuberculosis</i> was the most common pathogen overall. Systemic risk factors for non-TB SRA included diabetes, immunosuppression, HIV, and recent COVID-19. All patients with TB-SRA received anti-tubercular therapy with/without corticosteroids, while non‑TB SRA was treated with intravitreal and systemic targeted antimicrobials along with vitrectomy. Despite intravitreal and systemic therapy, visual outcomes remained poor, with no significant difference in final visual acuity between TB-SRA vs non-TB SRA (2.57 ± 1.92 vs 2.76 ± 1.71 LogMAR; <i>p</i> = 0.3) with many eyes progressing to no light perception (37.5% vs 35.3%).</p><p><strong>Conclusion: </strong>Non-TB etiology accounted for approximately two-thirds of all SRA and is associated with systemic immunosuppression, while TB-SRA is commonly associated with systemic TB. Microbiological diagnosis remains challenging, and clinical outcomes are often suboptimal.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-12"},"PeriodicalIF":1.7,"publicationDate":"2026-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Torpedo Maculopathy Complicated by Macular Neovascularization and Secondary Multiple Evanescent White Dot Syndrome.","authors":"Alexandre Barbé, Sarah Mrejen, Diana Bratu, Francesc March de Ribot, Nathalie Massamba, Christine Fardeau, Bahram Bodaghi, Sara Touhami","doi":"10.1080/09273948.2026.2736172","DOIUrl":"https://doi.org/10.1080/09273948.2026.2736172","url":null,"abstract":"<p><strong>Purpose: </strong>To report a case of torpedo maculopathy complicated by choroidal neovascularization (CNV) followed by secondary multiple evanescent white dot syndrome (MEWDS).</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 28-year-old male was referred for acute vision loss in his right eye. Fundus examination revealed a torpedo-shaped lesion temporal to the fovea. Optical coherence tomography (OCT) revealed a pigment epithelium detachment (PED) with overlying subretinal hyper-reflective material (SHRM), flow signal on OCT-angiography as well as hyper fluorescence on fluorescein angiography, consistent with CNV. More peripheral to the macula, indocyanine green angiography revealed multiple late-phase hypo fluorescent spots being hyper-autofluorescent on fundus autofluorescence and exhibiting ellipsoid zone disruption on OCT, supporting the diagnosis of secondary MEWDS.</p><p><strong>Conclusion: </strong>This is the first reported case of torpedo maculopathy complicated by both CNV and MEWDS. This case study exemplifies how congenital macular anomalies can progress to neovascular and inflammatory complications.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-4"},"PeriodicalIF":1.7,"publicationDate":"2026-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Infliximab and Tofacitinib Therapy for Severe Refractory Juvenile Idiopathic Arthritis Associated Panuveitis: A Challenge, Dechallenge, Rechallenge Case Report.","authors":"Mohammad Zarei, Yasaman Moradipari, Faezeh Molaei, Vahid Ziaee, Mohammadreza Nazari, Ali Momeni, Arash Mirzaei, Nazanin Ebrahimiadib","doi":"10.1080/09273948.2026.2739458","DOIUrl":"https://doi.org/10.1080/09273948.2026.2739458","url":null,"abstract":"<p><strong>Purpose: </strong>To report a child with severe treatment-resistant juvenile idiopathic arthritis-associated uveitis (JIAU), characterized by panuveitis, diffuse retinal vascular leakage, and refractory cystoid macular edema.</p><p><strong>Methods: </strong>We describe the clinical course, treatment response, and challenge, dechallenge, and rechallenge sequence in a child with severe refractory JIAU treated with combined infliximab and tofacitinib therapy.</p><p><strong>Results: </strong>The patient showed marked improvement in ocular inflammation, macular edema, and visual acuity following addition of tofacitinib to ongoing infliximab therapy. Inflammation recurred after holding infliximab despite continuation of tofacitinib and improved again following reintroduction of infliximab.</p><p><strong>Conclusion: </strong>This challenge, dechallenge, and rechallenge sequence is consistent with a possible complementary effect of infliximab and tofacitinib in this patient. However, causality and pharmacologic synergy cannot be established from a single case. Combined tumor necrosis factor alpha and Janus kinase inhibition may represent an exceptional rescue approach for carefully selected patients with severe refractory JIAU, although its efficacy and long-term safety require further evaluation.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149063200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Follow-Up of Checkpoint Inhibitor-Associated Uveitis Treated with Fluocinolone Acetonide Intravitreal Implant in a Pediatric Patient.","authors":"Roselind L Ni, Lauren Diroff, Robert A Sisk, Veeral Shah, Lindsay Haacker, Brian Turpin, Virginia A Miraldi Utz","doi":"10.1080/09273948.2026.2735411","DOIUrl":"https://doi.org/10.1080/09273948.2026.2735411","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the clinical course and 2-year follow-up of a pediatric patient treated with 0.18 mg fluocinolone acetonide intravitreal implants (Yutiq, EyePoint Pharmaceuticals) for chronic, bilateral immune checkpoint inhibitor (ICI)-associated uveitis.</p><p><strong>Methods: </strong>Retrospective case report.</p><p><strong>Results: </strong>A 15-year-old female patient with advanced epithelioid peritoneal mesothelioma on pembrolizumab and ipilimumab therapy developed chronic, bilateral ICI-associated anterior and intermediate uveitis failing topical corticosteroids was treated with bilateral intravitreal 0.18 mg fluocinolone acetonide implants, avoiding systemic immunosuppression. One year later, severe steroid-induced ocular hypertension (IOP) OS developed after receiving high-dose systemic corticosteroids for life-threatening ICI-related rhabdomyolysis. Goniotomy controlled IOP, and cataract extraction 3 months later led to visual recovery.</p><p><strong>Conclusion: </strong>The intravitreal fluocinolone acetonide 0.18 mg implant may be an effective treatment for recalcitrant ICI-associated intermediate uveitis in the pediatric population, providing long-term control of inflammation while preserving immunotherapy effectiveness. Careful follow-up is needed to monitor for complications of uveitis and corticosteroid treatment.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-4"},"PeriodicalIF":1.7,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149062925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choroidal Involvement in Nodal Marginal Zone Lymphoma Presenting as Serous Retinal Detachment.","authors":"Kanpirom Tangpontirak, Natthaphop Peenatakapho, Chinadol Wanitpongpun, Wipada Laovirojjanakul","doi":"10.1080/09273948.2026.2736178","DOIUrl":"https://doi.org/10.1080/09273948.2026.2736178","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the clinical presentation and multimodal imaging findings of choroidal involvement in nodal marginal zone lymphoma (NMZL) presenting as serous retinal detachment and its response to systemic chemotherapy.</p><p><strong>Methods: </strong>Retrospective review of clinical records and multimodal imaging findings, with joint interpretation by a uveitis specialist and the hematology-oncology team.</p><p><strong>Results: </strong>A 63-year-old woman presented with decreased vision in the left eye and was found to have a shallow serous retinal detachment. Inflammatory choroiditis was initially suspected and systemic corticosteroids therapy was initiated, resulting in transient improvement. Subsequent examination revealed recurrent subretinal fluid with multiple subretinal yellow infiltrates and diffuse choroidal thickening after the steroid effect subsided. Optical coherence tomography demonstrated undulating retinal pigment epithelium. Choroidal lymphoma was considered, prompting thorough systemic investigation. Systemic imaging later identified axillary and intra-abdominal lymphadenopathy and a right breast mass. Histopathology of the breast lesion confirmed NMZL. The patient was treated with rituximab-based systemic chemotherapy with intrathecal chemotherapy, achieving partial systemic response and complete ocular remission.</p><p><strong>Conclusions: </strong>Choroidal involvement in NMZL is rare and may present as steroid-responsive but recurrent serous retinal detachment, mimicking inflammatory disease. Systemic evaluation with biopsy of accessible extraocular sites, in conjunction with compatible ocular findings, can establish the diagnosis while avoiding high-risk choroidal biopsy. Early recognition and multidisciplinary collaboration are essential to enable timely diagnosis and systemic treatment.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-5"},"PeriodicalIF":1.7,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149063191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab in Refractory Non-Infectious Uveitis, Scleritis, and Idiopathic Orbital Inflammatory Syndrome: A Real-World Single-Centre Retrospective Case Series from Türkiye.","authors":"Murat Oklar, Burak Tanyıldız, Nilüfer Zorlutuna Kaymak, Ezgi Tanyeri Kılınç, Ahmet Kasım Kılıç, Mehmet Engin Tezcan","doi":"10.1080/09273948.2026.2735420","DOIUrl":"https://doi.org/10.1080/09273948.2026.2735420","url":null,"abstract":"<p><strong>Purpose: </strong>To describe outcomes and safety of rituximab (RTX) in refractory non-infectious uveitis, scleritis, and idiopathic orbital inflammatory syndrome (IOIS).</p><p><strong>Methods: </strong>Single-centre retrospective series of eleven consecutive patients (21 eyes; one unilateral) treated with intravenous RTX (1,000 mg twice, 14 days apart, then six-monthly maintenance) between January 2023 and May 2026. Response was graded by at least two of three uveitis specialists.</p><p><strong>Results: </strong>Mean follow-up was 19.0 months (3.9 cycles). Diagnoses were granulomatosis with polyangiitis (GPA; <i>n</i> = 3, PR3-ANCA positive), Vogt-Koyanagi-Harada disease (<i>n</i> = 2), demyelinating disease-associated uveitis (<i>n</i> = 2), and one each of IOIS, presumed juvenile sarcoidosis, lupus, and rheumatoid arthritis. Visual acuity was unchanged (logMAR 0.51 to 0.42; <i>p</i> = 0.272). Mean daily prednisolone-equivalent dose fell from 28.0 to 3.5 mg (87.7% relative reduction; <i>p</i> = 0.002). Modified McCluskey scores fell from 14.25 to 1.50 (<i>n</i> = 4); PR3-ANCA titres declined in all three GPA patients. Ten of eleven patients (90.9%) responded (five complete, five partial), including nine of ten (90.0%) with active ocular inflammation at initiation. The non-responder had sclerosing orbital disease. One herpes zoster reactivation occurred.      .</p><p><strong>Conclusions: </strong>In this small, heterogeneous cohort, RTX was associated with marked corticosteroid sparing and favourable responses in all three subtypes. Both demyelinating cases responded, a two-patient observation relevant where anti-TNF is contraindicated. Absent visual gain likely reflects pre-existing damage. Because most patients continued an antimetabolite with corticosteroid premedication, the independent effect of RTX cannot be isolated.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-12"},"PeriodicalIF":1.7,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149062944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}